Treximet is a migraine treatment drug owned by Currax. The drug, which is available in tablet form, contains Naproxen Sodium and Sumatriptan Succinate as active ingredients. It was first authorized for market use on 15 April, 2008.
The generic version of Treximet will possibly be available after 02 April, 2026. The last patent protecting this drug, titled 'Multilayer dosage forms containing NSAIDs and triptans', will expire on this date.
Treximet is primarily used as an acute treatment for migraines. Its effectiveness is due to its two active ingredients, Naproxen Sodium and Sumatriptan Succinate, which work together to alleviate the symptoms of a migraine.
Treximet is protected by a total of 2 patents, none of which have expired. The last patent on this drug, which covers multilayer dosage forms containing NSAIDs and triptans, expires on 02 April, 2026. Treximet generic versions are expected to be released following this date. Below are the details of the patent: